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Background: Visceral adiposity contributes to cardiometabolic risk, and visceral adiposity index (VAI) had significant
correlation with visceral adiposity. We aimed to explore whether VAI was associated with cardiac structure and
function and assess the impact of the cut-off points of VAI defining visceral adipose dysfunction (VAD) on the severity
of coronary heart disease (CHD).
Methods: A total of 95 patients with CHD were divided into Control (nondiabetic CHD patients) and DM group
(diabetic CHD patients). Then the two groups were respectively divided into VAD absent and VAD groups. Clinical,
echocardiographic and coronary artery angiographic indexes were acquired to examine in relation to VAI.
Results: A significant increasing trend among the four groups of patients (Control + VAD absent, Control +VAD, DM +
VAD absent and DM +VAD groups) were observed for waist circumference (WC), body mass index (BMI), systolic blood
pressure (SBP), glucose, VAI and Gensini score (P<0.05 for all). The following variables were associated with VAI: total
cholesterol, nonesterified fatty acid, Waist-Hip ratio and SBP. VAI was independently associated with Gensini score.
Conclusions: The extent of CHD was more severe in diabetes, and VAI as a simple indicator of visceral adipose mass
was strongly associated with the severity of CHD. The cut-off points of VAI used for defining VAD were more useful in
diabetic CHD patients in identifying the severity of CHD.
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The increased prevalence of obesity contributes to car-
diovascular disease (CVD) risk [1]. However, not every
obese patient develops CVD. In this regard, visceral adi-
posity has been found to play a key role in cardiometa-
bolic risk [2]. The precise measurement of the total
amount of body fat and its regional distribution is pos-
sible by using computed tomography (CT) or Magnetic
resonance imaging (MRI) [3], but they are costly and not
routinely available. Accordingly there is a need for sim-
ple techniques that can identify visceral adiposity, such
as waist circumference (WC), but WC alone does not* Correspondence: zhongmingzm@gmail.com
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unless otherwise stated.help in distinguishing between subcutaneous and vis-
ceral (both omental and mesenteric) fat mass [4]. Amato
et al [5] has recently developed a novel sex-specific
index based on WC, body mass index (BMI), triglyceride
(TG), and high-density lipoprotein (HDL) cholesterol
and termed it visceral adiposity index (VAI), and ob-
served that VAI had significant correlation with visceral
adiposity. And VAI showed a strong independent associ-
ation with cardiovascular risk [5]. Clinical studies have
indicated that visceral adipose tissue was associated with
cardiac structure and function [6]. However, the correla-
tions between VAI and cardiac structure and function as
well as that between VAI and the severity of coronary
heart disease (CHD) remain unclear.
Diabetes is a major risk factor of incident CVD and
VAI showed higher correlation with incident diabetesis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and HDL) [7]. However, the contribution of diabetes to
the severity of CHD remains unclear. Recently, Amato
et al identified in a Caucasian Sicilian population the
age-stratified cut-off points of VAI, patients with VAI
scores greater than these cut-off points were arbitrarily
defined as visceral adipose dysfunction (VAD) [8]. To
better understand the correlations between VAI and car-
diac structure and function and the impact of the cut-off
points of VAI defining VAD on the severity of CHD, we
used simple anthropometric measures, echocardiography
and coronary angiography and examined: first, whether
diabetes and VAD aggravated the severity of coronary
artery disease of CHD patients. Second, whether there
were other clinical influences of VAI. Finally, we deter-




We recruited 95 CHD patients diagnosed by coronary
angiography on admission to Qilu Hospital of Shandong
University with the complaints suggestive of angina or
myocardial infarction. All subjects were unrelated Chinese
Han nationality. Then, the selected CHD patients were di-
vided into two main groups: Control group (nondiabetic
CHD patients) and DM group (diabetic CHD patients).
Informed consent was obtained from all subjects based on
a protocol approved by the Ethics Committee of Qilu
Hospital of Shandong University.
Clinical assessment
The details of age, gender, weight and height were
obtained, with BMI calculated as the body weight in
kilograms divided by the height in meters squared. WC
was measured at the level of the umbilicus, systolic and
diastolic blood pressures (SBP and DBP) were obtained
with a mercury sphygmomanometer using auscultatory
methods. Blood was drawn after the participants had
fasted overnight. Levels of plasma total cholesterol (TC),
HDL, low-density lipoprotein (LDL) cholesterol, TG,
nonesterified fatty acid (NEFA) and fasting blood glucose
were measured by standard laboratory techniques.
VAI score was calculated as described [5] using the fol-
lowing sex-specific equations, when TG is Triglycerides
levels expressed in mmol/l and HDL is HDL-cholesterol
levels expressed in mmol/l:
Males: VAI ¼ WC








Females: VAI ¼ WC








Echocardiograms were obtained with a commercially
available ultrasound machine (Vivid 7; GE Vingemed
Ultrasound, Horten, Norway) with a 2.5 or 3.5 MHZ
phased array transducer. Participants were examined in
the left lateral decubitus position and images were ac-
quired at passive end expiration to minimise global car-
diac movement from standard parasternal long axis and
apical planes.
The M-mode echocardiographic study of the left ven-
tricles performed under 2D control. The ventricular
septal (VS) and posterior wall (PW) thicknesses at end-
diastole, and left ventricular end-diastolic dimensions
(LVDd) were determined from M-mode echocardiogram
by American Society of Echocardiography recommenda-
tions. The left ventricular ejection fraction (LVEF) was
estimated by the modified Simpson method and was
used as the parameter of left ventricular (LV) systolic
function.
Gensini score
To assess the severity of CHD, we used the Gensini
scoring system [9]. Coronary artery score equals the sum
of all segment scores (where each segment score equals
segment weighting factor multiplied by severity score).
Severity scores assigned to the specific percentage lu-
minal diameter reduction of the coronary artery segment
are 32 for 100%, 16 for 99%, 8 for 90%, 4 for 75%, 2 for
50%, and 1 for 25%.
Statistical analysis
Data are presented as mean ± SD for continuous vari-
ables and as proportions for categoric variables. One-
way ANOVA was used to compare the differences
among groups of participants. Stepwise multiple regres-
sion analysis was performed to determine the correl-
ation and independent variables for VAI as well as
Gensini score. Statistical analyses were performed using
SPSS 17.0 (SPSS Inc., Chicago, IL) software. A two-tailed
P value < 0.05 was considered statistically significant.
Results
The demographic and clinical characteristics of the
CHD participants are shown in Table 1. The subjects in-
cluded 60 males and 35 females, and their mean age was
60.89 ± 8.66 years. There were no significant differences
in age, gender, smoking, aspirin and stain treatments be-
tween Control group and DM group. DM group had sig-
nificantly higher body weight, WC, Waist-Hip ratio, SBP,
BMI, fasting glucose, TC, TG, NEFA and Gensini score
and lower HDL which showed that diabetes mellius had
more serious glucose metabolic disorders, dyslipidemia
and coronary lesion.
Table 1 Baseline characteristic of CHD patients with or
without diabetes
Control (n = 57) DM (n =38) P
Age (years) 60.09 ± 9.10 61.68 ± 8.45 0.391
Gender (M/F) 38/19 22/16 0.396
Body weight (kg) 66.03 ± 7.97 70.21 ± 7.87 0.014
WC (cm) 91.00 ± 6.67 97.18 ± 7.64 0.000
Waist-Hip ratio 0.95 ± 0.04 0.97 ± 0.06 0.015
BMI (kg/m2) 24.72 ± 2.63 26.13 ± 2.59 0.012
SBP (mmHg) 130.81 ± 16.32 142.05 ± 17.12 0.002
DBP (mmHg) 74.68 ± 7.93 74.55 ± 12.00 0.953
Glucose (mmol/l) 4.91 ± 0.64 7.35 ± 1.93 0.000
TC (mmol/l) 4.33 ± 0.94 4.77 ± 1.12 0.041
TG (mmol/l) 1.29 ± 0.64 1.59 ± 0.81 0.046
NEFA (mmol/l) 86.09 ± 51.86 115.95 ± 64.40 0.020
HDL (mmol/l) 1.19 ± 0.24 1.08 ± 0.22 0.035
LDL (mmol/l) 2.78 ± 0.77 2.83 ± 0.82 0.774
Gensini 63.47 ± 48.44 106.66 ± 32.91 0.000
VAI 1.80 ± 1.08 2.61 ± 1.59 0.008
Smoking 17 (0.30) 16 (0.42) 0.273
Hypertension 36 (0.63) 26 (0.68) 0.664
β-blocker 13 (0.23) 12 (0.32) 0.353
ACEI 7 (0.12) 5 (0.13) 1.000
ARB 6 (0.11) 4 (0.11) 1.000
Statin 11 (0.19) 7 (0.18) 1.000
Aspirin 26 (0.46) 18 (0.47) 1.000
Data are mean ± SD or n (proportion).
CHD: coronary heart disease; DM: diabetes mellitus; VAD: visceral adipose
dysfunction; WC: Waist circumference; BMI: body mass index; SBP: systolic blood
pressures; DBP: diastolic blood pressures; TC: Total cholesterol; TG: triglyceride;
NEFA: nonesterified fatty acid; HDL: high-density lipoprotein cholesterol;
LDL: low-density lipoprotein cholesterol; VAI: visceral adiposity index;
ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor
blocker.
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priate cut-off points of VAI for defining VAD were 2.52
for patients under 30 years, 2.23 for those aged between
30 and 42 years, 1.92 between 42 and 52 years, 1.93 be-
tween 52 and 66 years and 2.00 for patients over 66
years. We divided Control group into Control + VAD
absent group and Control +VAD group, and divided
DM group into DM + VAD absent group and DM +
VAD group. The baseline characteristics of the four
groups are shown in Table 2. A significant increasing
trend among the four groups of patients (Control +
VAD absent group, Control +VAD group, DM + VAD
absent group and DM + VAD group ) were observed
for body weight (P = 0.010), WC (P < 0.001), Waist-Hip
ratio (P = 0.024), BMI (P = 0.011), SBP (P = 0.020),
Glucose (P < 0.001), NEFA (P = 0.044) and VAI (P =
0.008). A significant increasing trend among the fourgroups of patients were also observed for Gensini score
(P = 0.001), but VAD and DM showed no significant
interaction (P=0.883). There were also significant differ-
ences in TG (P = 0.002) and HDL (P = 0.0016) among
the four groups.
After the adjustment for the effect of age, gender and
the four clinical indexes in the mathematical model of
VAI, the multivariate models including SBP, DBP, heart
rate, Waist-Hip ratio, Glucose, TC, LDL and NEFA fac-
tors. The following variables were associated with VAI:
TC, NEFA, Waist-Hip ratio and SBP (Table 3).
After the adjustment for the effect of age, gender, the
multivariate models including the ultrasonic parameters
left atrial (LA) diameter, LV diameter, right ventricular
(RV) diameter, aortic (AO) diameter, pulmonary artery
(PA) diameter, LVEF and left atrial dimension index
(LADI). The following variables were associated with
VAI: LADI and PA (Table 4).
Stepwise multiple linear regression analysis was also
used to determine independent variables of Gensini
score. The model included age, SBP, DBP, Glucose, TC,
LDL and VAI as independent variables and the analysis
revealed that VAI (OR 18.257 [95%CI 6.038-30.475]; P =
0.005) was independently associated with Gensini score.
Discussion
The study compared clinical indexes, cardiac structure
and function and the severity of coronary artery dis-
eases between nondiabetic CHD patients and diabetic
CHD patients. The major findings of the present study
lead us to the following conclusions: [1] The CHD pa-
tients without diabetes had no significant differences in
glucose and lipid metabolism disorders between VAD
absent group and VAD group, but the extent of CHD
of VAD group was more severe than VAD absent
group. However, VAD aggravated glucose and lipid me-
tabolism disorder and the severity of coronary artery
diseases of CHD patients with diabetes. [2] After
adjusting for age and sex, TC, NEFA, Waist-Hip ratio
and SBP contributed to VAI; [3] VAI had independent
association with Gensini score.
Diabetes is associated with an increased risk of car-
diovascular death and a higher incidence of CHD [10].
One of the features of diabetes is abdominal obesity,
and visceral adipose tissue plays an importance role in
the progress of diabetes. VAI was strongly associated
with incident diabetes. In this study, we found that
DM + VAD group had significant increases in glucose
and lipid metabolism disorders and the severity of
CHD, but the classification of VAD according to the
aged cut-off points of VAI had no obvious advantage in
CHD patients without diabetes. Consequently, VAD
which Amato et al. identified played a more importance
role in CHD patients with diabetes.
Table 2 Baseline characteristic of Control + VAD absent, Control + VAD, DM + VAD absent and Control + VAD patients
Control + VAD absent (n = 35) Control + VAD (n = 22) DM + VAD absent (n =17) DM + VAD (n =21) P
Age (years) 59.71 ± 9.09 60.68 ± 9.30 63.47 ± 9.59 60.24 ± 7.32 0.546
Gender (M/F) 25/10 13/9 13/4 9/12 0.102
Body weight (kg) 64.26 ± 6.80 68.86 ± 6.01* 69.09 ± 7.19* 71.12 ± 8.44* 0.010
WC (cm) 89.71 ± 5.95 93.05 ± 7.33 94.29 ± 7.86* 99.52 ± 6.75*†# 0.000
Waist-Hip ratio 0.95 ± 0.04 0.95 ± 0.04 0.96 ± 0.05 0.99 ± 0.06*† 0.024
BMI (kg/m2) 24.49 ± 2.96 25.09 ± 2.00 25.18 ± 1.65 26.89 ± 2.98*†# 0.011
SBP (mmHg) 130.2 ± 14.31 131.8 ± 19.43 141.6 ± 19.30* 142.4 ± 15.64*† 0.020
DBP (mmHg) 73.51 ± 7.30 76.55 ± 8.70 72.47 ± 13.00 76.24 ± 11.15 0.439
Glucose (mmol/l) 4.87 ± 0.65 4.96 ± 0.64 7.19 ± 1.70*† 7.47 ± 2.13*† 0.000
TC (mmol/l) 4.36 ± 0.94 4.29 ± 0.95 4.46 ± 0.95 5.03 ± 1.21 0.067
TG (mmol/l) 1.27 ± 0.61 1.32 ± 0.71 1.17 ± 0.62 1.93 ± 0.19*†# 0.002
NEFA (mmol/l) 86.14 ± 50.51 86.00 ± 55.14 100.65 ± 60.90 128.3 ± 65.92*† 0.044
HDL (mmol/l) 1.23 ± 0.25 1.11 ± 0.20 1.176 ± 0.28 1.01 ± 0.12*# 0.006
LDL (mmol/l) 2.78 ± 0.79 2.79 ± 0.76 2.58 ± 0.62 3.03 ± 0.91 0.359
Gensini 52.66 ± 39.27 80.68 ± 30.63* 93.76 ± 20.07* 117.1 ± 37.76*†# 0.001
Smoking 12 (0.34) 5 (0.23) 12 (0.71) 4 (0.19) 0.004
Hypertension 24 (0.69) 12 (0.55) 12 (0.71) 14 (0.67) 0.679
β-blocker 9 (0.26) 4 (0.18) 4 (0.24) 8 (0.38) 0.507
ACEI 6 (0.17) 1 (0.06) 5 (0.29) 0 (0.00) 0.025
ARB 5 (0.14) 1 (0.06) 1 (0.06) 3 (0.14) 0.559
Statin 9 (0.26) 2 (0.09) 2 (0.12) 5 (0.24) 0.344
Aspirin 18 (0.51) 8 (0.36) 10 (0.59) 8 (0.38) 0.410
Data are mean ± SD or n (proportion).
VAD: visceral adipose dysfunction; DM: diabetes mellitus; WC: Waist circumference; BMI: Body mass index; SBP: systolic blood pressures; DBP: diastolic blood pressures;
TC: Total cholesterol; TG: triglyceride; NEFA: nonesterified fatty acid; HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; ACEI: angiotensin-
converting enzyme inhibitor; ARB: angiotensin receptor blocker. *P < 0.05 vs Control + VAD absent; †P < 0.05 vs Control+ VAD; #P < 0.05 vs DM+ VAD absent.
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and influences short and long term outcomes of patients
who smoke after diagnosis [11,12]. There is increasing
evidence that smoking affects body fat distribution and
that it is associated with central obesity [13]. Therefore,
smoking might contribute to VAI and be a risk factor
for VAD, thus aggravating the severity of CHD. Drug
therapy also influences the severity of CHD. Statin treat-
ment ameliorates the severity of CHD through theTable 3 Multiple linear regression for relation of VAI to
clinical factors
Beta R square P
TC (mmol/l) 0.395 0.148 <0.001
NEFA (μmol/dl) 0.313 0.200 0.001
Waist-Hip ratio 0.236 0.244 0.012
SBP (mmHg) 0.208 0.284 0.027
WC: Waist circumference; BMI: Body mass index; TG: triglyceride; TC: Total
cholesterol; NEFA: nonesterified fatty acid; SBP: systolic blood pressures.
Beta: Standardized Coefficients.control of plasma cholesterol level. Furthermore, it has
been demonstrated that statin treatment reduced adipos-
ity of ob/ob mice [14]. Aspirin is also a kind of drug
which can protect CHD through its antiplatelet effect
[15]. In this study, there were no significant differences
in smoking, statin and aspirin treatments between CHD
without diabetes and diabetic CHD. Therefore, the ef-
fects of smoking, statin and aspirin treatments are equal
between CHD without diabetes and diabetic CHD.
Previous studies have investigated that VAT/SAT (sub-
cutaneous adipose tissue) was associated with higher
SBP, DBP, lower HDL-cholesterol and higher TG [16]. InTable 4 Multiple linear regression for relation of VAI to
ultrasonic index
Beta R square P
LADI (mm/m2) 0.323 0.092 0.020
PA (mm) 0.299 0.181 0.030
VAI: visceral adiposity index; LADI: 1eft atrial dimension index; PA: pulmonary
artery; Beta: Standardized Coefficients.
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could also contribute to VAI. Visceral adipose tissue was
independently associated with left ventricular mass and
LA enlargement [6,17], and low levels of adiponectin re-
leased from adipose tissue are directly linked to the de-
velopment of pulmonary arterial hypertension [18]. Our
results suggested VAI was positively correlated with LA
and pulmonary artery enlargement and was independ-
ently associated with the severity of CHD.
Limitations
In our study, we defined VAD through the cut-off points
derived from a Caucasian Sicilian population that Amato
et al. study and found that VAD aggravated the severity
of CHD in Chinese adults, suggesting that the cut-off
points of VAI could be applied to CHD of Chinese in
some extent. However, the exact cut-off points of VAI
suitable for CHD of Chinese adult patients should be
determined.
Conclusions
In conclusion, the extent of CHD was more severe in
diabetes, and VAI as a simple indicator of visceral adi-
pose mass was strongly associated with the severity of
CHD. The cut-off points of VAI which Amato et al used
for defining VAD were more useful in CHD patients
with diabetes in identifying the severity of CHD.
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